Back to Search
Start Over
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
- Source :
- The New England Journal of Medicine. July 29, 1999, Vol. 341 Issue 5, p319, 9 p.
- Publication Year :
- 1999
-
Abstract
- Giving patients with coronary artery disease a stent plus the drug abciximab appears to be the most effective treatment for preventing a heart attack. A stent is a small cylindrical device that is inserted into an artery to keep it open. Abciximab is a drug that prevents the formation of blood clots. Researchers randomly assigned 2,399 patients with coronary artery disease to receive a stent only, a stent and abciximab, or balloon angioplasty plus abciximab. The lowest rate of heart attack and death occurred in the group that received a stent and abciximab.
Details
- ISSN :
- 00284793
- Volume :
- 341
- Issue :
- 5
- Database :
- Gale General OneFile
- Journal :
- The New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.55327327